MRNA vaccine takes on genital herpes in first human trial
NCT ID NCT07330440
First seen Jan 10, 2026 · Last updated May 02, 2026 · Updated 26 times
Summary
This early-stage study tests an mRNA vaccine designed to prevent genital herpes caused by HSV-2. About 144 healthy adults aged 18-55 will receive different doses to check safety and immune response. The vaccine aims to train the body to fight the virus, potentially stopping infection or outbreaks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENITAL HERPES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Jishuitan Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.